10,12-Tricosadiynoic acid

Name: 10,12-Tricosadiynoic acid
Brand: MedChemExpress
SKU: HY-135425
Rating: 5.0 (9 reviews)

Cat. No.: HY-135425 Purity: 99.95%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism. 10,12-Tricosadiynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

For research use only. We do not sell to patients.

CAS No. : 66990-30-5

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

9 Publications Citing Use of MCE 10,12-Tricosadiynoic acid

Bio/Physico-chemical Assay

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

RT-PCR

: 10,12-Tricosadiynoic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 29:e05436. [Abstract]; Effects of mild ACOX1 inhibition (30 µM, 10,12-Tricosadiynoic acid (ACOX1i) vs. DMSO, 72h) in the different pHe condi&ons with supplementa&on of 50 µM DHA (FA-free BSA as vehicle) (N=3, n=6).

: 10,12-Tricosadiynoic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 29:e05436. [Abstract]; 10,12-Tricosadiynoic acid (ACOX1i, 10 mg/kg) significantly reduced tumor growth in mice fed the ω3 PUFA‐rich diet, but not in those on the control diet.

: 10,12-Tricosadiynoic acid purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Mar;39(3):720-733. [Abstract]; 10,12-Tricosadiynoic acid (TDYA, 50 μM; 36 h) inhibited the activating phosphorylation of MET (MET Y1349/1356) and IGF1R (IGF1R Y1165/1166) in ARH77 cells, but had no effect on other proteins.

: 10,12-Tricosadiynoic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]; RT-qPCR detection of ACOX1 mRNA expression in mouse gastrocnemius muscle tissue. The results showed that 10,12-Tricosadiynoic acid (TA, 100 μg/kg; i.g.; once daily for 10 days) significantly inhibited the expression of ACOX1 mRNA.

: 10,12-Tricosadiynoic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]; Enzyme activity assay of ACOX1 in mouse gastrocnemius muscle tissues. NC: Normal Control group; Dex: Model group; FA: Model + FA group; TA: Model + TA group. The results showed that 10,12-Tricosadiynoic acid (TA, 100 μg/kg; i.g.; once daily for 10 days) significantly inhibited the enzyme activity of ACOX1.

: 10,12-Tricosadiynoic acid purchased from MedChemExpress. Usage Cited in: Environ Int. 2023 Aug:178:108138. [Abstract]; 10,12-Tricosadiynoic acid (TDYA, 5 μM; 72 h) co-administered with 50 μM PFOA or PFOS for 72 h significantly attenuated PFOA- and PFOS-induced mitochondrial membrane potential collapse in AML12 cells, compared with PFOA or PFOS treatment alone.

: 10,12-Tricosadiynoic acid purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jan:123:155183.; 10,12-Tricosadiynoic acid (TDYA, 24 h) significantly inhibited ACOX1 activity in AML12 cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Acyltransferase Isoform Specific Products:

View All Isoforms

ACAT1 ACAT2 MGAT2 ACAT DGAT1 DGAT2

Biological Activity
Purity & Documentation
References
Customer Review

Description

10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism^[1]. 10,12-Tricosadiynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

IC₅₀ & Target

Acyl-CoA oxidase-1 (ACOX1)^[1].

In Vitro

10,12-Tricosadiynoic acid-CoA rapidly inhibits ACOX1 activity in a time- and concentration-dependent manner. The activity of ACOX1 decreases by nearly 95% after 5 min of incubation with 10 eq of 10,12-Tricosadiynoic acid-CoA. ACOX1 activity is inhibited only if free 10,12-Tricosadiynoic Acid is activated as the CoA thioester, the substrate form. Inhibition of ACOX1 by 10,12-Tricosadiynoic acid-CoA is irreversible. And the kinetics parameters KI and kinact are calculated to be 680 nm and 3.18 min¹, respectively^[1].
10,12-Tricosadiynoic acid is the precursor of 10,12-Tricosadiynoic acid-CoA and is transformed into 10,12-Tricosadiynoic acid-CoA by peroxisomal very long chain acyl-CoA synthetase (VLACS) after entering into cells, and it inhibits ACOX1 in vivo^[1].
10,12-Tricosadiynoic acid (500 nM) inhibits acyl-CoA oxidase-1 (ACOX1) activity. 10,12-Tricosadiynoic acid treatment abrogates the protective effect by Sirt5 siRNA^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

10,12-Tricosadiynoic acid (100 μg/kg; oral gavage; daily; for 8 weeks; male Wistar rats) treatment increases hepatic mitochondrial fatty acid oxidation (FAO) via activation of the SIRT1-AMPK (adenosine 5′-monophosphate-activated protein kinase) pathway and proliferator activator receptor α and reduces hydrogen peroxide accumulation in high fat diet-fed rats, which significantly decreases hepatic lipid and ROS contents, reduces body weight gain, and decreases serum triglyceride and insulin levels^[1].
10,12-Tricosadiynoic acid (0 mg/kg, 37.5 mg/kg, 75 mg/kg, and 150 mg/kg diet) treatment does not affect weight gain, but significantly decreases peroxisomal β-oxidation in the liver, and increased body fat accumulation in Nile tilapia. The fish with impaired peroxisomal β-oxidation exhibited higher contents of serum lipid and peroxidation products, and alanine aminotransferase activity, and significantly lowered hepatic activities of superoxide dismutase and catalase^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (210-230 g) fed with high fat diet^[1]
Dosage:	100 μg/kg
Administration:	Oral gavage; daily; for 8 weeks
Result:	Reduced hydrogen peroxide accumulation in high fat diet-fed rats, which significantly decreased hepatic lipid and ROS contents, reduced body weight gain, and decreased serum triglyceride and insulin levels.

Molecular Weight

346.55

Formula

C₂₃H₃₈O₂

CAS No.

66990-30-5

Appearance

Solid

Color

Off-white to light blue

SMILES

CCCCCCCCCCC#CC#CCCCCCCCCC(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL (48.10 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8856 mL	14.4279 mL	28.8559 mL
5 mM	0.5771 mL	2.8856 mL	5.7712 mL
10 mM	0.2886 mL	1.4428 mL	2.8856 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (14.43 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (14.43 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (14.43 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.95%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (239 KB) HNMR (291 KB) RP-HPLC (208 KB) MS (181 KB)

Handling Instructions (2659 KB)

References

[1]. Zeng J, et al. Specific Inhibition of Acyl-CoA Oxidase-1 by an Acetylenic Acid Improves Hepatic Lipid and Reactive Oxygen Species (ROS) Metabolism in Rats Fed a High Fat Diet. J Biol Chem. 2017 Mar 3;292(9):3800-3809. [Content Brief]

[2]. Takuto Chiba, et al. Sirtuin 5 Regulates Proximal Tubule Fatty Acid Oxidation to Protect against AKI. J Am Soc Nephrol. 2019 Dec;30(12):2384-2398. [Content Brief]

[3]. Yan Liu, et al. Impaired peroxisomal fat oxidation induces hepatic lipid accumulation and oxidative damage in Nile tilapia. Fish Physiol Biochem. 2020 Aug;46(4):1229-1242. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8856 mL	14.4279 mL	28.8559 mL	72.1397 mL
	5 mM	0.5771 mL	2.8856 mL	5.7712 mL	14.4279 mL
	10 mM	0.2886 mL	1.4428 mL	2.8856 mL	7.2140 mL
	15 mM	0.1924 mL	0.9619 mL	1.9237 mL	4.8093 mL
	20 mM	0.1443 mL	0.7214 mL	1.4428 mL	3.6070 mL
	25 mM	0.1154 mL	0.5771 mL	1.1542 mL	2.8856 mL
	30 mM	0.0962 mL	0.4809 mL	0.9619 mL	2.4047 mL
	40 mM	0.0721 mL	0.3607 mL	0.7214 mL	1.8035 mL